Original Article

Prognostic model for brain metastases from lung adenocarcinoma identified with epidermal growth factor receptor mutation status

Hongwei Li1, Wei Li Wang1, Haixia Jia1, Jianhong Lian2, Jianzhong Cao1, Xiaqin Zhang1, Xing Song1, Sufang Jia1, Zhengran Li1, Xing Cao1, Wei Zhou1, Songye Han3, Weihua Yang3, Yanfen Xi4 & Shenming Lian1

1 Department of Radiation Oncology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, China
2 Department of Surgery, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, China
3 Department of Chemotherapy, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, China
4 Department of Pathology, Shanxi Provincial Cancer Hospital, Shanxi Medical University, Taiyuan, China

Keywords
Brain metastases; EGFR mutations; lung adenocarcinoma; prognostic.

Correspondence
Hongwei Li, Department of Radiotherapy, Shanxi Provincial Cancer Hospital, Shanxi Medical University, No. 3, Zhigongxinjian, Taiyuan, Shanxi 030013, China.
Tel: +86 351 465 1153
Fax: +86 351 465 1667
Email: 3420010@163.com

Hongwei Li and Wei Li Wang contributed equally to this work.

Received: 26 March 2017; Accepted: 8 May 2017.

doi: 10.1111/1759-7714.12460
Thoracic Cancer 8 (2017) 436–442

Abstract
Background: Several indices have been developed to predict survival of brain metastases (BM) based on prognostic factors. However, such models were designed for general brain metastases from different kinds of cancers, and prognostic factors vary between cancers and histological subtypes. Recently, studies have indicated that epidermal growth factor receptor (EGFR) mutation status may be a potential prognostic biological factor in BM from lung adenocarcinoma. Thus, we sought to define the role of EGFR mutation in prognoses and introduce a prognostic model specific for BM from lung adenocarcinoma.

Methods: Data of 256 patients with BM from lung adenocarcinoma identified with EGFR mutations were collected. Independent prognostic factors were confirmed using a Cox regression model. The new prognostic model was developed based on the results of multivariable analyses. The score of each factor was calculated by six-month survival. Prognostic groups were divided into low, medium, and high risk based on the total scores. The prediction ability of the new model was compared to the three existing models.

Results: EGFR mutation and Karnofsky performance status were independent prognostic factors and were thus integrated into the new prognostic model. The new model was superior to the three other scoring systems regarding the prediction of three, six, and 12-month survival by pairwise comparison of the area under the curve.

Conclusion: Our proposed prognostic model specific for BM from lung adenocarcinoma incorporating EGFR mutation status was valid in predicting patient survival. Further verification is warranted, with prospective testing using large sample sizes.

Introduction

Brain metastases (BM) are one of the leading causes of morbidity and mortality in patients with non-small cell lung cancer (NSCLC). The risk of developing BM in lung adenocarcinoma has been reported at 45%. Generally, prognosis of BM is poor, with median survival reported at one to two months in untreated BM patients. Whole brain radiotherapy (WBRT), the standard treatment method for BM, has improved median survival to four to six months, irrespective of histological subtype. To analyze the contributions of pretreatment variables to survival with BM and to select the appropriate treatment recommendations for individual patients, several scoring systems have been developed based on independent prognostic factors. The
widely accepted prognostic systems include recursive partitioning analysis (RPA), basic score for brain metastases (BS-BM), and the graded prognostic assessment index (GPA). However, prognostic factors vary between different cancers and their histological subtypes. For example, BM develops more commonly in NSCLC, small-cell lung cancer (SCLC), breast cancer, melanoma, and renal carcinoma, which all have different prognostic factors. Although a diagnosis-specific prognostic factors index (DS-GPA) was developed by Paul et al. it does not meet the needs of daily clinic practice.

In recent decades, epidermal growth factor receptor (EGFR) mutations have been shown to be an important biologic marker for NSCLC. EGFR mutations are more common in adenocarcinoma than squamous cell carcinoma, identified in 40–60% of Asian patients with adenocarcinoma. EGFR mutation status is significantly associated with therapeutic efficacy and progression-free survival (PFS) using EGFR-tyrosine kinase inhibitors (TKIs). Several studies have demonstrated that EGFR mutation status is an independent prognostic factor in BM from NSCLC, especially in patients with adenocarcinoma. This may suggest that these genotypes should be integrated into the prognostic scoring classification system in lung adenocarcinoma with BMs. We identified the specific prognostic factors in lung adenocarcinoma and designed a valid prognostic model integrated with genotypes suitable for patients with BM from lung adenocarcinoma.

Methods

Data of 1063 patients with BM from lung adenocarcinoma identified with EGFR mutations between August 2010 and May 2015 from the lung cancer medical database in our institute were reviewed. All patients were identified with EGFR mutation status by DNA direct sequencing or the amplification refractory mutation system. Patients who had BM since their diagnosis of NSCLC were included. Inclusion criteria were: patients diagnosed with pathologic types of lung adenocarcinoma; BM confirmed by enforced computed tomography or magnetic resonance imaging; detailed clinical and treatment data, and date of death or follow-up examination. Two hundred and fifty-six BM patients met the selection criteria. Patient-related variables were collected, including age, gender, Karnofsky performance status (KPS), status of primary lesion (controlled vs. uncontrolled), presence of extracranial systemic metastases (present vs. absent), number of brain metastases (single vs. multiple), and status of EGFR mutations. Treatment options included WBRT with 30–40 Gy in 10–20 fractions, management with EGFR-TKIs (gefitinib or erlotinib at a daily dose of 150 mg or 250 mg), or a combination of these two treatments.

The primary endpoint of this study was the overall survival (OS) rate, defined as the date of BM diagnosis to death or the last follow-up. Differences in survival rates by patients and treatment variables were analyzed in univariable and multivariable tests. The new prognostic classification model was developed based on the results of multivariable analyses (Table 1). Following Rades et al., the score of each factor was determined by six-month survival rates (Table 2). The total prognostic scores were obtained from the sum of the scores for each factor. Prognostic groups were divided into high (A), medium (B), and low risk (C) groups based on the total scores. Patients were also grouped by the previous common scoring systems of RPA, GPA, and BS-BM. The prediction ability of the different models in this group of patients was compared.

The Kaplan–Meier method was used to calculate the OS rate. A log-rank test was performed to explore the impact of variables on survival rates and survival difference of groups in different prognostic models. Multivariable analysis was performed using a Cox proportional hazards model to define the independent prognostic factors. The area under the receiver operating characteristic curve was used to define predictive ability. The area under the curve (AUC) of the new prognostic model and the other three scoring systems were compared regarding the prediction of three, six, and 12 month survival. A P value of <0.05 was considered statistically significant. An AUC value of 0.5 indicated no diagnostic value of the models. The low, medium, and high values refer to 0.5–0.7, 0.7–0.9 and 0.9 or more, respectively. All analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) and MedCalc version 15 (MedCalc Software, Ostend, Belgium).

Results

Patient characteristics

Patient age ranged from 28 to 79 years old (median 57 years) and 0.138 (53.9%) patients were male. The sample included 142 (55.5%) cases of primary lung cancer with synchronous BM and 114 (44.5%) of metachronous BM. In 187 cases (73.05%), the brain was the first site of distant metastases, while 77 patients (30.1%) presented with BM as the solitary metastases site at the time of BM diagnosis. One hundred and five (41%) BM patients had single metastases, 81 (31.6%) had two to three lesions, and 70 (27.3%) had four or more lesions. At the time of BM diagnosis, 61 patients (23.8%) were confirmed with controlled primary tumors and 179 (69.9%) had extracranial metastases. KPS scores were 72 (28.1%) <70, 154 (60.2%) 70–80, and 30 (11.7%) 90–100. In the entire sample,
108 patients (42.2%) had EGFR mutations, including 45 (17.6%) with exon 19 deletions, 51 (19.9%) with 21 point mutations (L858R, L861Q etc.), and nine (3.5%) with other rare mutations (20 or 18). The remaining three (1.2%) patients had two or more EGFR mutations. Of the 256 cases, 173 patients received treatment for BM: 127 received WBRT with 30–40 Gy in 10–20 fractions, 85 received EGFR-TKIs, and 39 received a combination of the two treatments (Table 1).

**Prognostic model from lung adenocarcinoma integrated with genotypes**

At the end of follow-up, 78 (30.5%) patients were still alive. The median survival of whole group was 10.13 months (95% confidence interval 8.176–12.084). Univariate and multivariate analyses of prognostic factors is shown in Table 1. The log-rank test identified gender, KPS, EGFR, and treatment with...
EGFR-TKIs as significant factors associated with survival. In the Cox regression model, only KPS and EGFR mutation status were independently associated with survival. These two independent factors were integrated into the new prognostic system. The scores of each factor are shown in Table 2. The total scores ranged from 8.5 to 18 (Fig 1). The patients were divided into three groups: A, with scores of 8.5–10.5 presenting high risk; B, with 14–16 presenting medium risk; and C group had the lowest risk with scores of 16–18.

Evaluation of the predictive ability of different models

The results of Kaplan–Meier curves are presented in Figure 2. Differences in treatment methods between the models were tested using log-rank analysis; the results showed \( P < 0.001 \) in all groups (Fig 3). The area under the receiver operating characteristic curve was used to show the prediction results in three, six, and 12-month survival in the four prognostic scoring systems (Table 3) and pairwise comparison was carried out. The new prognostic model was superior to the three other scoring systems regarding the prediction of three, six, and 12-month survival (Table 4). The AUCs in the new prognostic model were 0.802, 0.775, and 0.752 respectively. The new prognostic model showed the most powerful predictive ability.

Discussion

The most common prognostic classification systems in BM include GPA, BSBM, and RPA, and their efficacy has been validated in previous studies. However, these prognostic models were designed for a heterogeneous population and prognostic factors vary between different cancers and their histological subtypes. The optimal treatment for BM patients is also different in various patient subsets. The previous prognostic indices might not meet the current needs in clinical assessment specific to BM in different cancers. In recent years, EGFR mutation has been recognized as an important biologic marker in lung adenocarcinoma for therapeutic efficacy and PFS of EGFR-TKI treatment. We have integrated EGFR mutation status into a new prognostic model for BM from...
lung adenocarcinoma, which proved superior to the three other scoring systems regarding the prediction of three, six, and 12-month survival.

Many previous studies have confirmed that pretreatment prognostic factors in patients, such as age <65, KPS >70, number of metastases, controlled primary and no extracranial metastases are associated with good prognoses in BM from NSCLC. In this era of personalized treatment, potential oncogenes were also correlated with patient survival. Our results indicate that KPS score and EGFR mutation status are independently associated with survival, consistent with the results of previous studies by Lee et al., Hsiao et al., and Gow et al.10–12 The traditional treatment options for BM include surgery for a single lesion in a non-eloquent region, stereotactic radiosurgery for oligometastases with less than three lesions, and WBRT for multi-metastases. Recently, with the development of molecular biology in lung cancer, it has been reported that EGFR-TKIs could achieve better responses for NSCLC BM patients with EGFR mutations. Wu et al. conducted a phase II study in 48 BM patients with EGFR mutations treated with EGFR-TKIs. The median OS and PFS were 18.9 and 9.67 months, respectively.22 Jamal-Hanjani et al. reported that NSCLC BM patients with EGFR mutations treated with EGFR-TKIs achieved a median OS of 12.9–18.8 months.23 Targeted therapy using EGFR-TKIs is now recognized as an effective treatment option in NSCLC BM patients.24 To develop an appropriate prognostic model specifically for BM from lung adenocarcinoma and to assist clinicians to select optimal treatment, EGFR mutation status should be integrated into prognostic systems.

Recursive partitioning analysis was the first prognostic index for BM, developed by Gaspar et al. in 1997 from 1200

### Table 3 Area under ROC curve of each scoring model to predict survival

| Survival Time          | Scoring Model       | Area under ROC curve | P    | 95% CI       |
|------------------------|---------------------|----------------------|------|--------------|
| Three month survival   | New scoring model   | 0.788                | <0.001 | 0.717–0.859 |
|                        | GPA                 | 0.71                 | <0.001 | 0.634–0.785 |
|                        | RPA                 | 0.785                | <0.001 | 0.712–0.857 |
|                        | BSBM                | 0.626                | 0.005  | 0.550–0.703 |
| Six month survival     | New scoring model   | 0.757                | <0.001 | 0.698–0.815 |
|                        | GPA                 | 0.652                | <0.001 | 0.589–0.715 |
|                        | RPA                 | 0.749                | <0.001 | 0.689–0.809 |
|                        | BSBM                | 0.668                | <0.001 | 0.607–0.729 |
| Twelve month survival  | New scoring model   | 0.721                | <0.001 | 0.663–0.778 |
|                        | GPA                 | 0.651                | <0.001 | 0.584–0.716 |
|                        | RPA                 | 0.682                | <0.001 | 0.622–0.741 |
|                        | BSBM                | 0.719                | <0.001 | 0.657–0.780 |

BSBM, basic score for brain metastases; CI, confidence interval; GPA, graded prognostic assessment index; ROC, receiver operating characteristic; RPA, recursive partitioning analysis.
DS-GPA was developed. The prognostic factors in the cant diagnosis-specific GPA system.6 The values ranged from 0 to 4 and are now eliminating this factor and adding the BM numbers into the fiated their prognostic index based on a total of 1960 cases in patients with different primary tumors. To identify signi
nostic index for BM has not been de

Table 4 Pairwise comparison of ROC curves between the new scoring model and GPA, BSBM, RPA

| Group | GPA | BSBM | RPA |
|-------|-----|------|-----|
|       | 3 months | 6 months | 12 months | 3 months | 6 months | 12 months | 3 months | 6 months | 12 months |
| Z     | 2.197 | 3.521 | 2.341 | 3.407 | 2.532 | 0.0559 | 1.06 | 1.615 | 2.512 |
| P     | 0.028 | 0.0004 | 0.0192 | 0.0007 | 0.0114 | 0.9554 | 0.2894 | 0.1062 | 0.012 |

BSBM, basic score for brain metastases; GPA, graded prognostic assessment index; ROC, receiver operating characteristic; RPA, recursive partitioning analysis.

cases receiving radiotherapy in Radiation Therapy Oncology Group randomized trials. The system divided BM patients into three groups: level 1 include patients aged <65 years older, KPS >70, with primary tumor lesion control and no extracranial metastases; level 3 included patients with KPS <70; and all other cases were considered as level 2. The reliability of this prognostic system has been demonstrated in many studies since its introduction.7 To simplify the grouping method, Lorenzoni et al. proposed another prognostic index, known as the BS-BM, which assigns a value of 1 to each of three prognostic factors: KPS, primary lesion control, and the existence of extracranial metastases. The total scores of each factor are categorized into three levels. Another widely accepted prognostic index is the GPA system. However, primary tumor control cannot be defined objectively. The GPA system incorporates the number of BM but does not take into account primary tumor control, and thus has some subjectivity in clinical practice.7 Sperduto et al. generated their prognostic index based on a total of 1960 cases in five Radiation Therapy Oncology Group clinical trials by eliminating this factor and adding the BM numbers into the GPA system.8 The values ranged from 0 to 4 and are now widely adopted in clinical practice.7 However, the ideal prognostic index for BM has not been defined, especially for patients with different primary tumors. To identify significant diagnosis-specific prognostic factors and indices, the DS-GPA was developed. The prognostic factors in the NSCLC DS-GPA are the same as in the GPA.8 As our results showed that EGFR mutation in lung adenocarcinoma indicated prognostic value for BM, we incorporated EGFR mutation status into our prognostic model. This may be more suitable than the previous prognostic models for these specific BM patients. We also categorized our patient sample into the GPA, BSBM, and RPA systems separately. Log-rank testing showed prognostic differences between the three models. While all were proven to have predictive ability, our proposed model was superior when comparing the area under the receiver operating characteristic curve to test prediction of three, six, and 12-month survival. As our prognostic model had the highest predictive value in this cohort of patients, it may be used to assess patient progression, make treatment decisions, and compare clinical trials specific for patients with BM from lung adenocarcinoma. Its applicabil-
arity warrants further validation.

As a preliminary study, there are several limitations. Firstly, because of the retrospective nature, bias may have been introduced in the patient sample. Female non-smokers have the highest rates of EGFR mutation.25,26 As EGFR mutation status is easier to detect in these patients, this may have reduced the reproducibility of our model to some extent. Secondly, we could not validate our proposed model because of the relatively small sample size. All of the patients in this study were from Chinese populations, and the rate of EGFR mutation in lung adenocarcinoma is different between ethnic groups. It has been reported that EGFR mutation rates in Asian patients are higher than in Westerners, at rates of 50% and 20%, respectively.27,28 As such, our prognostic model may be more suitable to Asian patients. Finally, we used two kinds of test methods that might have different positive detectable rates of EGFR mutations. This would underestimate the scores in a small group of patients with false negative testing results, which should be addressed in future prospective research.

In summary, this retrospective study of a cohort of patients with BM from lung adenocarcinoma identified with EGFR mutations has confirmed that performance status and EGFR mutations were significant prognostic factors. Although the existing three prognostic systems are valid for BM from lung adenocarcinoma, our proposed prognostic model is more powerful in terms of predictive ability. It is specific for BM from lung adenocarcinoma and is the first to incorporate EGFR mutation status. Verification of our model via prospective testing with large sample sizes is warranted.

**Disclosure**

No authors report any conflict of interest.

**References**

1 Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. *Int J Cancer* 2013; 132: 1133–45.
2 Sørensen JB, Hansen HH, Hansen M, Dombernowsky P. Brain metastases in adenocarcinoma of the lung: Frequency, risk groups, and prognosis. *J Clin Oncol* 1988; 6: 1474–80.
Prognostic factors for brain metastases

H. Li et al.

3 Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR. Factors associated with the development of brain metastases: Analysis of 975 patients with early stage non-small cell lung cancer. Cancer 2010; 116: 5038–46.

4 Gaspar LE, Mehta MP, Patchell RA et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 17–32.

5 Gaspar L, Scott C, Rotman M et al. Recursive partitioning analysis (RPA) of prognostic factors 316 in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997; 37: 745–51.

6 Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008; 70: 510–4.

7 Lorenzoni J, Devriendt D, Massager N et al. Radiosurgery for treatment of brain metastases: Estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys 2004; 60: 218–24.

8 Sperduto PW, Chao ST, Sneed PK et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010; 77: 655–61.

9 Shi Y, Au JS, Thongprasert S et al. Epidermal growth factor receptor mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 2014; 9: 154–62.

10 Lee HL, Chung TS, Ting LL et al. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases. Radiat Oncol 2012; 7: 181.

11 Hsiao SH, Lin HC, Chou YT et al. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients. Lung Cancer 2013; 81: 455–61.

12 Gow CH, Chien CR, Chang YL et al. Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res 2008; 14: 162–8.

13 Rades D, Dziggel L, Segedin B et al. A new survival score for patients with brain metastases from non-small cell lung cancer. Strahlenther Onkol 2013; 189: 77–81.

14 Nieder C, Nestle U, Rotafar B, Walter K, Niewald M, Schnabel K. Prognostic factors in brain metastases: Should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes? Int J Radiat Oncol Biol Phys 2000; 46: 297–302.

15 Fleckenstein K, Hof H, Lohr F, Wenz F, Wannenmacher M. Prognostic factors for brain metastases after whole brain radiotherapy. Data from a single institution. Strahlenther Onkol 2004; 180: 268–73.

16 Antoni D, Noël G. [Radiotherapy of brain metastases according to the GPA score (Graded Prognostic Assessment).] Cancer Radiother 2013; 17: 424–7. (In French.)

17 Nieder C, Geinitz H, Molls M. Validation of the graded prognostic assessment index for surgically treated patients with brain metastases. Anticancer Res 2008; 28: 3015–7.

18 Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–57.

19 Inoue A, Kobayashi K, Maemondo M et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013; 24: 54–9.

20 Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121–8.

21 Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735–42.

22 Wu YL, Zhou C, Cheng Y et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: A phase II study (CTONG-0803). Ann Oncol 2013; 24: 993–9.

23 Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res 2012; 18: 938–44.

24 Greenhalgh J, Dwan K, Boland A et al. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev 2016; CD010383.

25 Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung cancer in never-smokers--a review. Eur J Cancer 2012; 48: 1299–311.

26 Ou SH. Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy? J Clin Pathol 2013; 66: 839–46.

27 Soh J, Toyooka S, Matsuo T et al. Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma. Oncol Lett 2015; 10: 1775–82.

28 Bauml J, Mick R, Zhang Y et al. Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist? Lung Cancer 2013; 81: 347–53.